Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment

Ying Wang, Mingfei Li, Lewis E. Kazis, Weiming Xia

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Introduction: Alzheimer's disease (AD) and COVID-19 share common risk factors including hypertension. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are frequently prescribed antihypertension medications. Methods: This study analyzed 436,823 veterans tested for SARS-CoV-2 infection. We conducted both classical and propensity score weighted logistic models to compare COVID-19 outcomes between patients with AD or mild cognitive impairment (MCI) to those without cognitive impairment, and examined effect of ACEI/ARB prescription. Results: There was a statistically significant association between AD and increased odds of infection and mortality. MCI was not found to be a risk factor for infection. Subjects with MCI exhibited poor clinical outcomes. Prescribing ARBs but not ACEIs was significantly associated with a lower risk of COVID-19 occurrence among AD and MCI patients. Discussion: Exploring beneficial effects of existing medications to reduce the impact of COVID-19 on patients with AD or MCI is highly significant. Highlights: There is significant association between Alzheimer's disease (AD) and increased risk of COVID-19 infection and odds of mortality. Subjects with mild cognitive impairment (MCI) defined by claims data exhibit poor clinical outcomes, but MCI was not found to be a risk factor for severe acute respiratory syndrome coronavirus 2 infection. Prescribing angiotensin II receptor blockers was significantly associated with a lower risk of COVID-19 occurrence among AD/MCI patients.

Original languageEnglish (US)
Pages (from-to)911-923
Number of pages13
JournalAlzheimer's and Dementia
Volume18
Issue number5
DOIs
StatePublished - May 2022

Keywords

  • Alzheimer's disease
  • COVID-19
  • angiotensin II receptor blockers
  • angiotensin converting enzyme inhibitors
  • mild cognitive impairment
  • severe acute respiratory syndrome coronavirus 2

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment'. Together they form a unique fingerprint.

Cite this